Names without a link are companies not yet registered in OpenBizGraph
§05
Network
NETWORK
Loading the relationship graph...
Drag to move · click to open
§06
History
139 EVENTS
Founded by Kohei Sawai and Noyo (pharmacist) in Asahi Ward, Osaka City, as the predecessor of Sawai Pharmaceutical Co., Ltd., Sawai Pharmacy.
Established Kaken Seiyaku Co., Ltd. in Kudan, Tokyo, with a capital of 190,000 yen.
Established Sawai Pharmaceutical Co., Ltd. (now Sawai Pharmaceutical Co., Ltd.) in Asahi Ward, Osaka City, with a capital of 195,000 yen.
Opened Tokyo Branch (now Tokyo First Branch).
Automated the production line at the head office factory (at that time).
Established Sapporo Sales Office (now Sapporo Branch), Tohoku Sales Office (now Sendai Branch), Nagoya Sales Office (now Nagoya Branch), and Fukuoka Sales Office (now Fukuoka Branch).
Obtained patent for garlic extract manufacturing method and launched vitamin B1 preparations.
Shifted from a manufacturer of over-the-counter drugs to a manufacturer of prescription drugs.
Completed Osaka Second Factory (at that time) in Asahi Ward, Osaka City.
Established a shipping center in Miyakojima Ward, Osaka City, to improve logistics from manufacturing to sales.
Completed the head office building (at that time) in Asahi Ward, Osaka City, and relocated the head office functions.
Jiro Sawai became President and CEO, and Hiroyuki Sawai was appointed Senior Managing Director.
Changed the company name to Sawai Pharmaceutical Co., Ltd.
Established Hiroshima Sales Office (now Hiroshima Branch).
Completed Kyushu Factory in Iizuka City, Fukuoka Prefecture.
Established Yaso Factory in Ishioka City, Ibaraki Prefecture.
Completed the second phase of Kyushu Factory (manufacturing equipment for general formulations and syrup formulations).
Established Osaka Research Institute (at that time) in Asahi Ward, Osaka City.
Established Medisa New Drug Co., Ltd. (now a consolidated subsidiary) in Chuo Ward, Tokyo.
Completion of the third phase construction of the Kyushu Factory (injectable drug manufacturing equipment).
Completion of the Kyushu Factory (currently Sawai Pharmaceutical Co., Ltd. Second Kyushu Factory) in Kaho District, Fukuoka Prefecture (now Iizuka City).
Jiro Sawai appointed as Chairman of the Board, Hiroyuki Sawai appointed as President and CEO.
Completion of the fourth phase construction of the Kyushu Factory (expansion of injectable drug manufacturing facilities, etc.).
Established a research and development center in Asahi-ku, Osaka City, to expand the R&D department.
Opened an Osaka branch.
Separated and established an independent shipping center, and established Active Work Co., Ltd., a wholly owned subsidiary.
Made Medisa New Drug Co., Ltd. a subsidiary.
Completion of the second phase construction of the Kyushu Factory (packaging equipment) at the current Sawai Pharmaceutical Co., Ltd. Second Kyushu Factory.
Completed the Mita Factory in Sanda City, Hyogo Prefecture.
Established a formulation research center (at that time) in Asahi-ku, Osaka City, to enhance formulation research.
Listed on the over-the-counter market of the Japan Securities Dealers Association.
Completion of the third phase construction of the Kyushu Factory (product warehouse, quality control analysis room, cafeteria, etc.) at the current Sawai Pharmaceutical Co., Ltd. Second Kyushu Factory.
Started publishing newspaper advertisements to promote awareness of generic medicines.
Completion of the fourth and fifth phase constructions of the Kyushu Factory (general formulation manufacturing equipment, automatic warehouse expansion).
Expanded injectable drug manufacturing facilities at the Kyushu Factory.
Listed on the Second Section of the Tokyo Stock Exchange.
Completion of the fifth phase construction of the Kyushu Factory (oral sustained-release formulations, etc., manufacturing equipment, packaging equipment).
Designated on the First Section of the Tokyo Stock Exchange.
Established a new visual identity.
Started broadcasting TV commercials nationwide.
Merged with the consolidated subsidiary, Active Work Inc.
Completion of the second phase of the Sanda Factory (expansion of general formulation manufacturing equipment and special formulation equipment).
Acquired the Mobara Factory of Nippon Sieiling Co., Ltd. (now Bayer Yakuhin Ltd.) in Mobara City, Chiba Prefecture, and operated as the Kanto Factory.
Sumitomo Corporation Group invested in Medisa New Drug.
Relocated headquarters to Asahi-ku, Osaka City.
Completed new headquarters and research building in Yodogawa-ku, Osaka City.
Made Kaken Seiyaku Co., Ltd. a subsidiary through share acquisition.
Established a syringe building at the Kanto Factory.
Formulated corporate philosophy and code of conduct.
Completion of the 6th phase of the Kyushu Factory (current Sawai Pharmaceutical Co., Ltd. Second Kyushu Factory) expansion including oral solid dosage production equipment.
Relocated headquarters to Yodogawa-ku, Osaka City.
Hiroyuki Sawai was appointed Chairman and Mitsuo Sawai was appointed President.
Completion of the third phase of the Sanda Factory (expansion of general formulation manufacturing equipment).
Established Saitama Branch (now Tokyo Second Branch).
Established Formulation Research Center (later renamed Formulation Technology Center).
Fully acquired Medisa New Drug.
The anti-allergy drug "Cetirizine Hydrochloride OD Tablets 'Sawai'" received the Best Generic Drug Award from the Japan Generic Medicines Association.
Through company split, absorbed the production business of Medisa New Drug, and succeeded the Kyushu Factory as Sawai Pharmaceutical's Second Kyushu Factory.
Established a formulation factory at the Kanto Factory.
Sleep inducer "Zolpidem Tartrate OD Tablets "Sawai"" received the Generic Drug Encouragement Award.
Antiplatelet drug "Cilostazol OD Tablets "Sawai"" received the Asahi Kasei Drug Development Technology Award.
Inherit the Kashima Factory (Kamisunashi, Ibaraki Prefecture) and start operation.
Established a new development center in Suita City, Osaka Prefecture.
Completed the Mita West Factory in Sanda City, Hyogo Prefecture.
Pitabastatin tablets approved by the FDA.
Acquired Upsher-Smith Laboratories, LLC through Sawai America INC.
Celebrating the 90th anniversary of founding.
The packaging of Minodronate 50mg "Sawai" for osteoporosis treatment received the WorldStar Awards.
Signed a joint development and licensing agreement with NewGen Pharma for ALS treatment drugs.
Mitsuhiro Sawai appointed as Chairman of the Board, Kenzo Sawai as President and CEO.
Agreed on capital and business alliance with SumoMed Corporation.
Signed an exclusive development and sales agreement in Japan with NeuroReef for digital medical devices for migraines and depression.
Established Sawai Group Holdings Co., Ltd.
Mitsuhiro Sawai appointed as Chairman of the Board and President, Kenzo Sawai as Vice Chairman, and Kazuhiko Sueyoshi as President and CEO.
Launched the Personal Health Record (PHR) management app "SaluDi".
Established Trust PharmaTech Co., Ltd.
Signed a licensing agreement with CureApp Co., Ltd. for DTx development and sales in the NASH field.
Built a new injection building at the Kyushu factory.
Mitsuhiro Sawai appointed as Chairman and President.
Kimura Motohiko appointed as President and CEO.
Obtained approval for manufacturing and sales of non-invasive neuromodulation devices.
Sold Upsher-Smith Laboratories, LLC.
Established a new solid dosage building at the Second Kyushu Factory.
Entered into a licensing agreement with CureApp Inc. for the sale of alcohol reduction treatment support app.
Sawai Group Holdings acquires FrontAct Inc.
§07
News
9 ARTICLES
Sawai Group Achieves 100% Childcare Leave Take-up Rate Ahead of Schedule
Sawai Group Holdings achieved a 100% childcare leave take-up rate among male employees ahead of schedule in fiscal 2025, reaching 108%. Through continuous awareness reform and strengthening support systems, the goal was realized early.
Sawai Group Holdings Donates 10 Million Yen in Relief Funds
Sawai Group Holdings has donated 10 million yen as relief funds through the Japanese Red Cross Society to support victims and aid recovery from the Kumamoto Earthquake in Reiwa 8. They express their sympathy to the victims and pray for reconstruction.
Sawai Group Holdings, Social Bond Conditions Decided
Sawai Group Holdings has decided the conditions for issuing a domestic public offering social bond on July 24, 2026. The issuance amount is 10 billion yen, with a 10-year redemption period and an interest rate of 3.441%. The funds will be used for investments in subsidiaries and for capital investment in a factory in Fukui Prefecture.
Sawai Group Holdings Adoption Forest Signing Ceremony Participation
Sawai Group Holdings participated in the signing ceremony in support of the Adopt Forest system in Osaka Prefecture, promoting activities for the conservation of forests and farmland.
Sawai Group Holdings Personnel Changes Announcement
Sawai Group Holdings will implement personnel changes, transferring Mr. Yoshihiro Nishihara to the position of Director and Group Finance Department Manager, effective July 1, 2026.
Sawai Group Announces Subsidiary Merger
Sawai Group Holdings has decided to absorb and merge its consolidated subsidiary, Trust Pharmatech, into Sawai Pharmaceutical on April 1, 2027.
Sawai Group Holdings Certified as a Health Management Excellence Corporation 2026
Sawai Group Holdings has been selected as a Health Management Excellence Corporation 2026 and is working on employee health management and improving the workplace environment.
Sawai Group Holdings Personnel Changes Announcement
Sawai Group Holdings will implement personnel changes for multiple executives effective April 1, 2026.
Sawai Group Holdings Notice of Discontinuation of Sending Greetings for Director Reorganization
Sawai Group Holdings announced that, in order to promote environmental considerations and digitalization, they will cease sending greetings for director reorganization and will provide information about the future director system on their website.
§08
Public records
GOV
National Tax Agency basic information8120001236516
Source: National Tax Agency Corporate Number Publication Site, basic three items
Trade name
サワイグループホールディングス株式会社
Trade name (kana)
サワイグループホールディングス
Name in English
Corporation type
301
Address
〒532-0003 大阪府大阪市淀川区宮原5丁目2番30号
Postal code
5320003
Prefecture code
27
City code
123
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2021-04-12
Update date
2021-04-12
Change date
2021-04-12
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
01
Correction type
0
Trade name image ID
Address image ID
Sequence number
4372780
METI gBizINFO8120001236516
Source: gBizINFO (Ministry of Economy, Trade and Industry)